标题：阿托伐他汀改善老年慢性阻塞性肺疾病急性加重期患者肺功能的疗效观察

      作者：赵蔚诗，罗兆文，黄颖欣    (广州市荔湾区中医医院内科，广东 广州 510160)

      卷次： 2017年28卷8期

      【摘要】 目的 探讨阿托伐他汀对老年慢性阻塞性肺疾病急性加重期(AECOPD)患者血清炎症因子及肺功能的影响。方法 选择 2015年 6月至 2016年 6月间我院呼吸科收治的 86例老年AECOPD患者，根据随机数字表法随机分为两组，每组 43例，对照组予抗感染等常规治疗，观察组在此基础上联合应用阿托伐他汀治疗，疗程均为 14 d。比较两组患者治疗前后的血清炎症因子和肺功能的变化。结果 治疗后，观察组与对照组组患者的血清超敏C反应蛋白(hs-CRP)分别为(13.54±4.28) mg/L和(20.18±6.24) mg/L，较治疗前明显降低，肺功能指标第 1秒用力呼气量与用力肺活量的比值(FEV1/FVC)以及FEV1占预计值百分比(FEV1/预计值)分别为(56.41±8.32)%、(53.42±6.14)%和(52.33±8.41)%、(50.41±5.32)%，均较治疗前明显提高，差异均有统计学意义(P<0.05)；治疗后，观察组患者的血清 hs-CRP明显低于对照组，FEV1/FVC、FEV1/预计值明显高于对照组，差异均有统计学意义(P<0.05)。结论 阿托伐他汀治疗老年慢性阻塞性肺疾病急性加重期患者可有效抑制炎症反应、改善患者肺功能。
      【关键词】 慢性阻塞性肺疾病；阿托伐他汀；肺功能；炎症反应
      【中图分类号】 R563 【文献标识码】 A 【文章编号】 1003—6350（2017）08—1332—02

Effect of atorvastatin on lung function in elderly patients with acute exacerbations of chronic obstructivepulmonary disease.
ZHAO Wei-shi, LUO Zhao-wen, HUANG Ying-xin. Department of Internal Medicine, TraditionalChinese Medicine Hospital of Liwan District of Guangzhou, Guangzhou 510160, Guangdong, CHINA
【Abstract】 Objective To investigate the clinical efficacy of atorvastatin on inflammatory cytokines andlung function in elderly patients with acute exacerbations of chronic obstructive pulmonary disease (AECOPD).Methods From June 2015 to June 2016, 86 elderly AECOPD patients treated in Respiratory Department of ourhospital were randomly divided into two groups according to the random number table, each with 43 cases. The controlgroup was treated with conventional anti-infection treatment, and the observation group was treated additionally withatorvastatin, for 14 days. Before and after treatment, serum inflammatory factors and lung function changes were com-pared. Results After treatment, serum high-sensitivity C reactive protein (hs-CRP) in the observation group and thecontrol group respectively were (13.54 ± 4.28) mg/L and (20.18 ± 6.24) mg/L, significantly lower than those before treat-ment. The ratio of forced expiratory volume in 1 second to forced vital capacity (FEV1/FVC) and FEV1 percentage of es-timated value (FEV1/predictive) were (56.41 ± 8.32)% , (53.42 ± 6.14)% in the observation group and (52.33 ± 8.41)% ,(50.41±5.32)% in the control group, which were all significantly improved than before treatment (P<0.05). After treat-ment, the serum hs-CRP was significantly lower than that in the control group, and FEV1/FVC, FEV1/predictive valueswere significantly higher (P<0.05). Conclusion Atorvastatin in the treatment of elderly AECOPD patients can inhibitinflammation and improve lung function.
      【Key words】 Chronic obstructive pulmonary disease; Atorvastatin; Lung function; Inflammation·临床经验·doi:10.3969/j.issn.1003-6350.2017.08.045